Using different exercise treatments to improve cardiorespiratory fitness in young, insufficiently active but otherwise healthy females. Other
Conditions
Interventions
Briefly, participants will be assigned via block randomization following a 1:1 allocation ratio to either low-volume sprint-interval training (LVSIT) or moderate intensity continuous training (MICT).
Sponsors
McMaster University
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Biologically female 2. Aged 18–35 years 3. Insufficiently active based on self-report of not achieving 150 min of moderate to vigorous aerobic physical activity per the Canadian 24-h Movement Guidelines for Adults and deemed generally safe engage in physical activity per completion of the Canadian Society for Exercise Physiology Get Active Questionnaire (GAQ)
Exclusion criteria
Exclusion criteria: Not meeting inclusion criteria
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Peak oxygen uptake (VO2peak) will be determined by a progressive exercise test to maximal voluntary exertion using an electromagnetically braked cycle ergometer (Lode Excalibur Sport V2.0, Groningen, The Netherlands). Gas exchange and ventilatory variables will be continuously determined using a metabolic cart (Quark CPET metabolic cart, COSMED, Italy). Data will be averaged over 10-s intervals and VO2peak will be defined as the highest 30-s average over three consecutive intervals. VO2peak will be measured in duplicate before and after the 12-week intervention. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Heart rate measured (Polar A3, Finland) during exercise across all testing and training sessions. 2. Body mass measured using scale before and after the 12-week intervention . 3. Hippocampal-dependent learning and memory measured using the optimized Mnemonic Similarities Task (oMST), before and after the 12-week intervention. 4. Respiratory gases (VCO2, VO2, RER, VE) measured during exercise using metabolic cart (Quark CPET metabolic cart, COSMED, Italy) before and after the 12-week intervention and during select training sessions. Note that post-testing includes two separate trials i.e., at the same absolute and relative intensity as compared to baseline . 5. Serum: BDNF, Plasma: BDNF, cortisol, epinephrine, norepinephrine and insulin measured using commercially available assays, before and after the 12-week intervention . Note that post-testing includes two separate trials i.e., absolute and relative trials to baseline. Blood will be sampled at rest and prior to the cessation of exercise during each submaximal test. 6. [glucose], [pH], [lactate], pCO2, pO2 measured using blood analyzer cards (EPOC; Siemens Healthcare, Ontario, Canada) before and after the 12-week intervention. Note that post-testing includes two separate trials i.e., absolute and relative trials to baseline. Blood will be sampled at rest and prior to the cessation of exercise during each submaximal test. 7. Complete blood count analysis measured by Hamilton Regional Laboratory Medicine Program, Core Laboratory located at McMaster University Medical Centre before and after the 12-week intervention. Note that post-testing includes two separate trials i.e., absolute and relative trials to baseline. Blood will be sampled at rest and prior to the cessation of exercise during each submaximal test. 8. Rating of perceived exertion measured using the Borg Scale, before and after the 12-week intervention, including during training visits. | — |
Countries
Canada
Contacts
Public ContactMartin Gibala
Outcome results
None listed